International Stem Cell CORP (ISCO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 4M 8M 12M FY10: 1.6M FY11: 4.5M FY12: 4.6M FY13: 6.1M FY14: 7M FY15: 7.6M FY16: 7.2M FY17: 7.5M FY18: 11.1M FY19: 9.5M FY20: 7.1M FY21: 7.2M FY22: 8.2M FY23: 7.8M FY24: 9.1M FY25: 9.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 2.5M 5M 7.5M FY10: 843K FY11: 2.9M FY12: 3.3M FY13: 4.5M FY14: 5.1M FY15: 5.5M FY16: 5.2M FY17: 5.3M FY18: 7M FY19: 5.5M FY20: 4.3M FY21: 4.2M FY22: 4.9M FY23: 4.6M FY24: 5.3M FY25: 5.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-12M -8M -4M 0 4M 8M 12M FY10: -10.5M FY11: -11.4M FY12: -9.8M FY13: -7.5M FY14: -8.7M FY15: -4.6M FY16: -4.9M FY17: -4.9M FY18: -3.5M FY19: -5.7M FY20: -2.8M FY21: -1.9M FY22: -183K FY23: -663K FY24: -68K FY25: -267K FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-15M -10M -5M 0 5M 10M 15M FY06: -6.6M FY07: -6.1M FY08: -6.6M FY09: -8.5M FY10: -12.7M FY11: -9.2M FY12: -9.8M FY13: -10.5M FY14: -12.5M FY15: -2.6M FY16: -1.1M FY17: -6.1M FY18: -2.1M FY19: -4.3M FY20: -2.7M FY21: -899K FY22: -331K FY23: -131K FY24: -209K FY25: -418K FY07 FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 1.5M 3M 4.5M FY10: 725K FY11: 1.6M FY12: 1.3M FY13: 1.6M FY14: 1.9M FY15: 2.1M FY16: 1.9M FY17: 2.1M FY18: 4.1M FY19: 3.9M FY20: 2.8M FY21: 2.9M FY22: 3.3M FY23: 3.2M FY24: 3.8M FY25: 4M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-7.5M -5M -2.5M 0 2.5M 5M 7.5M FY10: -6.9M FY11: -7M FY12: -6.7M FY13: -5.6M FY14: -6.4M FY15: -4.1M FY16: -4.2M FY17: -2.1M FY18: -1.1M FY19: -1.4M FY20: -341K FY21: -1.3M FY22: 332K FY23: 929K FY24: 13K FY25: 8K FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-9M -6M -3M 0 3M 6M 9M FY10: -7.2M FY11: -7.5M FY12: -6.9M FY13: -5.8M FY14: -6.7M FY15: -4.2M FY16: -4.4M FY17: -2.3M FY18: -1.3M FY19: -1.6M FY20: -369K FY21: -1.3M FY22: 331K FY23: 849K FY24: -153K FY25: -35K FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 3M 6M 9M FY14: 1.2M FY15: 2M FY16: 3.2M FY17: 4.2M FY18: 6.4M FY21: 7.8M FY22: 8M FY23: 8M FY24: 8M FY25: 8M FY14 FY15 FY16 FY17 FY18 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '11: -0.11 Q1 '12: -0.14 Q2 '12: -0.14 Q3 '12: -0.13 Q4 '12: -0.13 Q1 '13: -0.10 Q2 '13: -0.09 Q3 '13: -0.10 Q4 '13: -0.09 Q1 '14: -0.08 Q2 '14: -3.94 Q3 '14: -5.31 Q4 '14: -9.10 Q1 '15: -10.16 Q2 '15: -6.80 Q3 '15: -5.68 Q4 '15: -2.44 Q1 '16: -6.56 Q4 '17: -1.86 Q1 '18: -1.22 Q2 '18: -1.03 Q3 '18: -0.47 Q4 '18: -0.33 Q1 '19: -0.31 Q2 '19: -0.34 Q3 '19: -0.36 Q4 '19: -0.57 Q1 '20: -0.50 Q2 '20: -0.55 Q3 '20: -0.62 Q4 '20: -0.35 Q1 '21: -0.38 Q2 '21: -0.21 Q3 '21: -0.16 Q4 '21: -0.11 Q1 '22: -0.03 Q2 '22: -0.06 Q3 '22: -0.08 Q4 '22: -0.04 Q1 '23: -0.04 Q2 '23: -0.01 Q3 '23: 0.01 Q4 '23: -0.02 Q1 '24: -0.05 Q2 '24: -0.07 Q3 '24: -0.07 Q4 '24: -0.04 Q1 '25: -0.04 Q2 '25: -0.04 Q3 '25: -0.02 Q4 '25: -0.06 Q1 '26: -0.06 Q2 '26: -0.08 Q3 '12 Q2 '14 Q1 '16 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.